Todd Chappell, Chief Operating Officer at Korro Bio, brings twenty years of product development and product strategy experience. He previously served as senior vice president of strategy and portfolio planning at Korro Bio.
Todd is a veteran industry executive who has led several early-stage therapeutic programs from discovery stage through to clinical trials. Most recently, he served as CEO for two seed-staged companies, Rasio Therapeutics, Inc. and Perceptive Navigation, LLC. Prior to being CEO, Mr. Chappell managed a portfolio of start-up pharmaceutical and medical device companies as an entrepreneur-in-residence at a private-public partnership involving Johns Hopkins University, National Institutes of Health, Medimmune, NEA, and SROne. From 2009 to 2012, Todd ran Shape Pharmaceuticals, Inc., a portfolio company of HealthCare Ventures, LLC, where he oversaw all day-to-day operations for the development of a novel HDAC inhibitor for Cutaneous-T-Cell-Lymphoma. Prior to Shape, Mr. Chappell was at CombinatoRx, Inc. for eight years and served as Executive Director of New Products. In that role, Mr. Chappell led the advancement of three programs from assay stage into human clinical studies.
Todd holds a B.S. from University of California at Los Angeles and a MBA from Boston University.
What is Todd Chappell's net worth?
The estimated net worth of Todd Chappell is at least $230.80 thousand as of June 16th, 2026. Mr. Chappell owns 16,964 shares of Korro Bio stock worth more than $230,795 as of August 10th. This net worth approximation does not reflect any other investments that Mr. Chappell may own. Learn More about Todd Chappell's net worth.
How do I contact Todd Chappell?
Has Todd Chappell been buying or selling shares of Korro Bio?
Todd Chappell has not been actively trading shares of Korro Bio during the past quarter. Most recently, Todd Chappell sold 3,168 shares of the business's stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $10.83, for a transaction totalling $34,309.44. Following the completion of the sale, the chief operating officer now directly owns 16,964 shares of the company's stock, valued at $183,720.12. Learn More on Todd Chappell's trading history.
Who are Korro Bio's active insiders?
Are insiders buying or selling shares of Korro Bio?
During the last twelve months, Korro Bio insiders bought shares 9 times. They purchased a total of 1,657,320 shares worth more than $18,412,560.00. During the last twelve months, insiders at the sold shares 9 times. They sold a total of 306,026 shares worth more than $4,309,636.75. The most recent insider tranaction occured on July, 6th when Director Jean Francois Formela sold 9,323 shares worth more than $130,149.08. Insiders at Korro Bio own 4.8% of the company.
Learn More about insider trades at Korro Bio. Information on this page was last updated on 7/6/2026.
